Revolution Medicines. has been granted a patent for macrocyclic compounds that modulate biological processes by forming complexes with presenter proteins and target proteins, such as CEP250. These compounds enhance target protein activity through specific interactions, requiring both protein-compound and protein-protein interactions for effective modulation. GlobalData’s report on Revolution Medicines gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Revolution Medicines, Cancer treatment biomarkers was a key innovation area identified from patents. Revolution Medicines's grant share as of June 2024 was 13%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US11987590B2 outlines a novel macrocyclic compound designed to interact with specific target proteins through a unique binding mechanism. The compound features two key components: a target protein interacting moiety and a presenter protein binding moiety. This design allows the compound to form a complex with a presenter protein, which enhances its binding affinity to the target protein by at least five-fold compared to the individual components. The patent specifies that the target protein can be CEP250, and the presenter protein may include prolyl isomerases. Various structural formulas for both the target protein interacting moiety and the presenter protein binding moiety are provided, indicating a range of potential compounds and their pharmaceutically acceptable salts.
Additionally, the patent claims methods for modulating target proteins, treating various conditions such as cancer, ciliopathies, and infections, and inhibiting prolyl isomerase activity. These methods involve administering an effective amount of the macrocyclic compound to a subject, either alone or in combination with a presenter protein, to achieve the desired therapeutic effect. The patent also describes the formation of a tripartite complex that includes the target protein, the presenter protein, and the compound, further emphasizing the innovative approach to protein interaction and modulation presented in this invention.
To know more about GlobalData’s detailed insights on Revolution Medicines, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
